References
- Iosif C, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984;63:257–60
- Iosif C. Effects of protracted administration of estriol on the lower urogenital tract in post-menopausal women. Arch Gynecol Obstet 1992; 51:115–20
- Heimer G, Samsioe G. Effects of vaginally delivered estrogens. Acta Obstet Gynecol Scand Suppl 1996;163:1–2
- Rigg L. Absorption of estrogens from vaginal creams. N Engl J Med 1978;278:195–7
- Matsson LA, Cullberg G, Eriksson 0, Knutsson F. Vaginal administration of low-dose oestradiol — effects on the endometrium and vaginal cytology. Maturitas 1989,11:217–22
- Sindberg Erikson P, Rasmussen H. Low-dose 17 beta estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo con-trolled study. Eur J Obstet Gynaecol Reprod Biol 1992;44:137–44
- Nilsson K, Heimer G. Low-dose estradiol in the treatment of urogenital oestrogen deficiency — a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121–7
- Weisberg E, Fraser IS, Mishell DR Jr, Lacarra M. The acceptability of a combined oestrogen/ progestogen contraceptive vaginal ring. Contra-ception 1995;51:39–44
- Nash HA, Alverez-Sanchez F, Mishell DR Jr, Fraser IS, Maruo T, Harmon TM. Estradiol-delivering vaginal rings for hormone replace-ment therapy. Am J Obstet Gynecol 1999;181:1400–6
- Dezarnaulds G, Fraser IS. Vaginal ring delivery of hormone replacement therapy — a review. Expert Opin Pharmacother 2002;4:201–12
- Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003;102:823–34
- Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with a conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351–8
- Key T, Pike M. The dose-effect relationship between 'unopposed' oestrogens and endome-trial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Macmil-lan Press Ltd, 1988:205–12
- Boman K, Strang P, Backstrom T, Gerdes U, Stendahl U. Influence of oestrogen on growth of endo-metrial carcinoma. Anticancer Res 1990;10:173–6
- Barberi R. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740–5
- Johansson C, Gunnarsson P. Pharmacokinetics of estradiol after application of an estradiol releasing vaginal ring. Research Report No: 20466 F, Kabi Pharmacia AB, Sweden, 1992
- Hustin J, van den Eynde JP. Cytological evalua-tion of the effect of various estrogens given in menopause. Acta Cytol 1977;21:225–8
- Coates H, King A. The Subject Assessment. A Handbook for Therapists. Edinburgh: Churchill Livingstone, 1982:91.
- Skoldefors H, Carlstrom K, Furuhjelm M. Aging and urinary oestrogen excretion in the male. Acta Obstet Gynecol Scand 1975;54:89–90
- Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epide-miol 1998;51:903–12
- Casper F, Petri E and the Vaginal Ring Study Group. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multi-center study. Int Urogynecol J 1999;10:171–6
- Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;7:73–80
- Dessole S, Rubattu G, Abrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004; 11:49–56
- Naessen T, Rodriguiz-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944–7
- Bounds W, Szarewski A, Lowe D, Guillebaud J. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 1993;48:123–5
- Weisberg E, Fraser IS, Baker J, et al. A randomised comparison of the effects on vaginal and cervical epithelium of a placebo ring with non-use of a ring. Contraception 2000;62:83–9
- Henriksson L, Stjernquist M, Boquist L, Cederg-ren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estrogen releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85–92
- Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo con-trolled study. Eur J Obstet Gynecol Reprod Biol 1992;44:137–44
- Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7: 140–2
- Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal wo-men. Am J Obstet Gynecol 1999;180:1072–9